# OnCo record dasatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dasatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dasatinib" ;
  schema:name "Dasatinib"@en ;
  schema:description "Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all."@en ;
  schema:url <https://onco.cc/drugs/dasatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dasatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q419940> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dasatinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (BCR::ABL1, SRC)" ;
  schema:alternateName "Sprycel" ;
  onco:approval "US 2006: CML and Ph+ ALL resistant or intolerant to imatinib", "US 2018: Paediatric Ph+ ALL with chemotherapy" ;
  onco:acceleratedApproval "US 2006-06-28: Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib", "US 2010-10-28: Newly diagnosed adults with Philadelphia chromosome-positive CML in chronic phase" ;
  onco:acceleratedApprovalConfirmed "US 2009-05-21: Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib", "US 2015-08-12: Newly diagnosed adults with Philadelphia chromosome-positive CML in chronic phase" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-ph-positive/>, <https://onco.cc/cancers/all-ph-like/>, <https://onco.cc/cancers/cml-chronic-phase/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/ddr2/>, <https://onco.cc/targets/abl1/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/ph-positive-all/> ;
  onco:trials <https://onco.cc/trials/d-alba/>, <https://onco.cc/trials/nct04971226/> .